These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 37221577)

  • 1. Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma.
    Lin H; Fu L; Li P; Zhu J; Xu Q; Wang Y; Mumin MA; Zhou X; Chen Y; Shu G; Yao G; Chen M; Lu J; Zhang L; Liu Y; Zhao Y; Bao J; Chen W; Luo J; Li X; Chen Z; Cao J
    J Transl Med; 2023 May; 21(1):343. PubMed ID: 37221577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty acid metabolism affects hepatocellular carcinoma progression via the PPAR-γ signaling pathway and fatty acid β-oxidation.
    Feng W; Liang J; Xu B; Huang L; Xu Q; Chen D; Lai J; Chen J
    Int Immunopharmacol; 2024 Nov; 141():112917. PubMed ID: 39137630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
    Chen Y; He J; Jin T; Zhang Y; Ou Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
    Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
    Front Immunol; 2022; 13():967277. PubMed ID: 36466837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis of single-cell and bulk transcriptome identifies a signature based on NK cell marker genes to predict prognosis and therapeutic response in clear cell renal cell carcinoma.
    Wang K; Yu M; Zhang Z; Yin R; Chen Q; Zhao X; Yu H
    Transl Cancer Res; 2023 May; 12(5):1270-1289. PubMed ID: 37304554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
    He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel amino acid metabolism-related gene signature to predict prognosis in clear cell renal cell carcinoma.
    Cheng X; Deng W; Zhang Z; Zeng Z; Liu Y; Zhou X; Zhang C; Wang G
    Front Genet; 2022; 13():982162. PubMed ID: 36118874
    [No Abstract]   [Full Text] [Related]  

  • 9. Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.
    Tan D; Miao D; Zhao C; Shi J; Lv Q; Xiong Z; Yang H; Zhang X
    BMC Cancer; 2023 Mar; 23(1):264. PubMed ID: 36949462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma.
    Sorokina M; Stupichev D; Lyu Y; Ramachandran A; Miheecheva N; Brown JH; Nomie K; Postovalova E; Bagaev A; Tsiper M; Hsieh JJ
    Clin Genitourin Cancer; 2021 Dec; 19(6):e374-e381. PubMed ID: 34389275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
    Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
    Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
    Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a combined hypoxia- and metabolism-related prognostic signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma.
    Wu X; Xie W; Gong B; Fu B; Chen W; Zhou L; Luo L
    Front Oncol; 2023; 13():1162846. PubMed ID: 38023248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma.
    Bao W; Han Q; Guan X; Wang Z; Gu M
    Oncol Res; 2023; 31(2):181-192. PubMed ID: 37304236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty acid metabolism-related lncRNAs are potential biomarkers for survival prediction in clear cell renal cell carcinoma.
    Zhang MQ; Yang BZ; Wang ZQ; Guo S
    Medicine (Baltimore); 2024 Feb; 103(8):e37207. PubMed ID: 38394500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAF2 promotes M2-polarized tumor-associated macrophage infiltration, angiogenesis and cancer progression by inhibiting autophagy in clear cell renal cell carcinoma.
    Xu Y; Li L; Yang W; Zhang K; Zhang Z; Yu C; Qiu J; Cai L; Gong Y; Zhang Z; Zhou J; Gong K
    J Exp Clin Cancer Res; 2023 Jul; 42(1):159. PubMed ID: 37415241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.
    Denize T; Hou Y; Pignon JC; Walton E; West DJ; Freeman GJ; Braun DA; Wu CJ; Gupta S; Motzer RJ; Atkins MB; McDermott D; Choueiri TK; Shukla SA; Signoretti S
    Clin Cancer Res; 2022 Sep; 28(18):4045-4055. PubMed ID: 35802667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
    Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
    Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.